

# The Nagoya Protocol & its implementation in the EU

What does it mean for biodiscovery?

Greifswald, 23/08/2018










# The Origins of ABS

### Since entry into force of CBD (1993):

Convention on Biological Diversity

Access and Benefit-sharing (ABS) as 3<sup>rd</sup> CBD objective

"... fair and equitable sharing of the benefits arising out of the utilization of genetic resources, including by appropriate access to genetic resources and by appropriate transfer of relevant technologies, taking into account all rights over those resources and to technologies, and by appropriate funding." (Art. 1 CBD)



- Clarification: states have sovereign rights over their (biological & genetic) resources (Art. 3 CBD)
- ABS as innovative instrument for biodiv conservation.



# The Origins of ABS: Article 15 CBD

### **ABS** principles according to CBD:

Art. 15(1)

 Sovereign rights of states over their (biological) resources, incl. right to regulate access to GR

Art. 15(2)

• Create conditions to facilitate access to GR

Art. 15(4)

 Access based on mutually agreed terms (MAT)

Art. 15(5)

 Access subject to prior informed consent (PIC), unless otherwise determined

Art. 15(7)

 Take measures with the aim of fair & equitable sharing of benefits from utilization




# From CBD to Nagoya Protocol





# Nagoya Protocol - Status Quo





## Nagoya Protocol - Main Content

#### The **ABC** of ABS

- A ccess: internat. "standards" / criteria for domestic access measures (Art. 6(3), 8 NP)
- B enefit-sharing: based on MAT (incl. IPLCs) (Art. 5 NP)
- **C** ompliance measures (Art. 15-17 & 18-20 NP)

### **Institutional provisions:**

- ABS National Focal Point (Art. 13(1) NP):
  - Information on ABS rules & procedures in provider state
- Competent National Authority(ies) (Art. 13(2) NP):
  - Responsible for implementation of ABS rules & procedures
- ABS Clearing-House (Art. 14 NP): <a href="https://absch.cbd.int/">https://absch.cbd.int/</a>



# Nagoya Protocol

Nagoya Protocol on Access and Benefit-sharing

## Article 36 AUTHENTIC TEXTS

The original of this Protocol, of which the Arabic, Chinese, English, French, Russian and Spanish texts are equally authentic, shall be deposited with the Secretary-General of the United Nations.

IN WITNESS WHEREOF the undersigned, being duly authorized to that effect, have signed this Protocol on the dates indicated.

DONE at Nagoya on this twenty-ninth day of October, two thousand and ten.

## MONETARY AND NON-MONETARY BENEFITS

- 1. Monetary kenefits may include, but not be limited to
  - (a) Access fees/fee per sample collected or otherwise acquired;
  - (b) Up-front payments;
  - (c) Milestone payments;
  - (d) Payment of royalties;
  - (e) Licence fees in case of commercialization;
  - Special fees to be paid to trust funds supporting conservation and sustainable use of biodiversity;
  - (g) Salaries and preferential terms where mutually agreed;
  - (h) Research funding;
  - (i) Joint ventures;
  - (j) Joint ownership of relevant intellectual property rights.
- 2. Non-monetary benefits may include, but not be limited to:
  - (a) Sharing of research and development results;
  - (b) Collaboration, cooperation and contribution in scientific research and development programmes, particularly biotechnological research activities, where possible in the Party providing genetic resources;

24

Nagoya Protocol on Access and Benefit-sharing


- (c) Participation in product development;
- (d) Collaboration, cooperation and contribution in education and training;
- (e) Admittance to ex situ facilities of genetic resources and to databases;
- (f) Transfer to the provider of the genetic resources of knowledge and technology under fair and most favourable terms, including on concessional and preferential terms where agreed, in particular, knowledge and technology that make use of genetic resources, including biotechnology, or that are relevant to the conservation and sustainable utilization of biological diversity;
- (g) Strengthening capacities for technology transfer;
- (h) Institutional capacity-building;
- Human and material resources to strengthen the capacities for the administration and enforcement of access regulations;
- Training related to genetic resources with the full participation of countries providing genetic resources, and where possible, in such countries;
- (k) Access to scientific information relevant to conservation and sustainable use of biological diversity, including biological inventories and taxonomic studies:
- (l) Contributions to the local economy;
- (m) Research directed towards priority needs, such as health and food security, taking into account domestic uses of genetic resources in the Party providing genetic resources;
- Institutional and professional relationships that can arise from an access and benefit-sharing agreement and subsequent collaborative activities;
- (o) Food and livelihood security benefits;
- (p) Social recognition;
- (q) Joint ownership of relevant intellectual property rights.

25



# **ABS Clearing-House**


#### Which countries are Parties to the NP?





# **ABS Clearing-House**

### **Country profiles:**





## Legal Framework in Germany

### A(ccess)

- Regulated by EU MS themselves
- In Germany, generally free (no PIC)

## **B**(enefit Sharing)

- Regulated by EU MS themselves
- In Germany, not required (no MAT)

## C(ompliance)

 Based on EU legislation




Regulation (EU) No 511/2014: Entry into force on 12.10.2014 Impl. Regulation (EU) 2015/1866: Entry into force on 9.11.2015 EU Guidance Document (EC) 2016/C 313/01: Published on 27.08.2016

- Implementing Act adopted on 25.11.2015
- Entry into force on 1.7.2016
- Party to Nagoya Protocol since 21.7.2016






# Scope of Regulation (EU) No 511/2014





## Scope of Regulation (EU) No 511/2014





## **Due Diligence System**

#### Art. 4 EU Reg.: General DD obligation

- User to ascertain that
  - GR/TK accessed in accordance with applicable ABS legislation
  - Benefits fairly & equitably shared upon MAT

Documentation obligation

- Seek
- Keep (20 years after utilization)
- Transfer
- Relevant documentation (Art. 4.3 a) or b))

Risk assessment obligation

- If insufficient information or uncertainties about legality of access & utilization
- PIC & MAT or equivalent to be obtained or
- Utilization to be discontinued (Art. 4.5)


Options for mitigating risks

- Acquisition of GR from registered collection (Art. 5)
- Recognized best practice (Art 8.2 EU Reg. or Art 20.2 NP)

Art. 7 EU Reg.: Obligations to file DD declarations




## **DD Declaration I**





## **DD Declaration II**






## **Submission of DDD**

#### **DECLARE**:









## **Submission of DDD**

#### **How to use DECLARE:**

 Registration of user institution through ECAS <u>https://webgate.ec.europa.eu/cas</u>



Login with ECAS-ID in DECLARE
 <a href="https://webgate.ec.europa.eu/declare/">https://webgate.ec.europa.eu/declare/</a>



Automated notification of BfN as CNA & activation of user institution



Automated notification of user institution after activation





## **Submission of DDD**

- User institution may navigate in DECLARE system
  - Adding further users of same or partnering institution
  - Drafting & submitting DDDs



Automated notification of BfN after submission of DDD



Reply to user or DDD forwarded to ABS CH



 Automated conversion into checkpoint communiqué published on ABS CH & notification of provider state

#### For further info see DECLARE User Guide:

http://ec.europa.eu/environment/nature/biodiversity/international/abs/pdf/Question%20and%20answer%20users.pdf



## Register of Collections

#### Art. 5 EU Reg.:

- Register established & maintained by Commission
- Application to & recognition by Member States
- Criteria to register collection or part of it:
  - Standardized procedures for exchanging samples of GR
  - Supply of GR only with appropriate documentation
  - Keep records of all samples of GR suppiled to 3<sup>rd</sup> persons
  - Establish or use unique identifiers where possible
  - Use appropriate tracking & monitoring tools
- Content of application: Annex I of Implementing Reg.



First (and so far only) registered collection in EU



## **Best Practices**

#### Art. 8 EU Reg.:

- Recognized by Commission
- Who can apply?
  - Association of users &
  - Other interested parties
- Criteria defined in EU Reg.
  - Combination of procedures, tools & mechanisms
  - Enabling user to comply with obligations under Art. 4 & 7
- Content of application: Annex IV of Implementing Reg.




## **Compliance Checks**

#### Art. 9 EU Reg. & Art. 5.4 EU Reg.:

- Compliance checks carried out by competent national authorities
- On the basis of
  - Periodically reviewed control plans using risk-based approach
  - Substantiated concerns
- Subject matter:
  - Due diligence obligation
  - DDDs
  - Criteria of registration



# **Competencies in Germany**





- ➤ ... Depending on the specific activity undertaken, both basic and applied research may be considered as "utilization" in the sense of the NP and EU Regulation. (EU Guicance Doc (EC) 2016/C 313/01; 2.3.3.)
- Litmus test: Users should ask themselves whether what they are doing with the GR creates new insight into **characteristics of the GR** which is of (potential) benefit to the further process of product development. If this is the case, the activity goes beyond mere description, should be considered research and therefore falls under the term "utilization".

(EU Guidance Doc (EC) 2016/C 313/01; 2.3.3.)



Quality checks, verification

Mere description of GR in phenotype-based research

Use of GR as testing/reference tools

Research on GR but not utilization

EU Reg not applicable

ABS Reg of provider states might be applicable



Identification through DNA sequencing, if no new knowledge on genetic and/or biochemical compositions is developed (e.g. no new species is being described)

Discovery, description and publication of a new species as long as it does not involve research on genetic and/or biochemical composistion of GR

Research on GR

<u>but not</u>

<u>utilization</u>

EU Reg not applicable

ABS Reg of provider states might be applicable



Research on GR leading
to isolation of
biochemical compound
used as new ingredient
(active or not)
incorporated in
product

Breeding program to create new plant variety based on naturally occuring plants

Genetic modification – creation of genetically modified animal, plant or microorganism containing a gene from another species

**Utilization** 

EU Reg applicable

ABS Reg of provider states applicable




## Digital Sequence Information



- Call by developing countries to include DSI within scope of NP
- CBD COP Decision XIII/16 & NP MOP Decision 2/14:
  - Consider (by COP XIV / MOP 3) any potential implications of use of DSI on GR for the 3 objectives of CBD & objective of NP
- Open process comprising following steps:
  - > 04-12/2017 Scoping study on terminology & concepts
  - 09/2017 Submission of views & information
  - 02/2018 Meeting of AHTEG
  - > 07/2018 SBSTTA to make recommendations
  - 11/2018 Negotiations at COP XIV / MOP 3



# **Digital Sequence Information**





## Thank You Very Much!





# **Credits**

Slide 2	"Logo Convention on Biological Diversity", https://www.cbd.int/
Slide 4	"Text of the Convention on Biological Diversity", <a href="www.cbd.int/programmes/outreach/awareness/publications.shtml">www.cbd.int/programmes/outreach/awareness/publications.shtml</a> , "Bonn Guidelines", <a href="www.cbd.int/abs/bonn/">www.cbd.int/abs/bonn/</a> , "World Summit on Sustainable Development", <a href="www.un.org/events/wssd/">www.un.org/events/wssd/</a> , "Logo COP 9", <a href="www.un.org/events/wssd/">www.un.org/events/wssd/</a> , "Logo COP 12", <a href="http://planttreaty.org/content/texts-treaty-official-versions">http://planttreaty.org/content/texts-treaty-official-versions</a> , "Pandemic influenza preparedness Framework", <a href="www.www.who.int/influenza/resources/pip">www.who.int/influenza/resources/pip</a> framework/en, "Logo UNDOALOS", <a href="http://www.un.org/Depts/los/convention_agreements/convention_overview_convention.htm">http://www.un.org/Depts/los/convention_agreements/convention_overview_convention.htm</a>
Slide 7	"Annex of the Nagoya Protocol", www.cbd.int/abs
Slides 8-9	"ABS Clearing-House", https://absch.cbd.int
Slide 10	"EUR-Lex Access to European Union law", <a href="http://eur-lex.europa.eu/legal-content/de/TXT/?uri=OJ:L:2014:150:TOC">http://eur-lex.europa.eu/legal-content/de/TXT/?uri=OJ:L:2014:150:TOC</a>
Slide 16	Graphics by the European Commission
Slide 19	"Logo of DSMZ", https://www.dsmz.de/
Slide 22	Logo of Robert Koch Institut, <a href="http://www.rki.de/DE/Home/homepage_node.html">http://www.rki.de/DE/Home/homepage_node.html</a> , Logo of Bundesanstalt für Landwirtschaft und Ernährung, <a href="http://www.ble.de/DE/00_Home/homepage_node.html">http://www.ble.de/DE/00_Home/homepage_node.html</a> , Logo of deutsches Patent- und Markenamt", <a href="http://www.dpma.de/">http://www.dpma.de/</a>
Slide 27	"Logo CBD COP XIII", https://www.cbd.int/conferences/2016
Slide 28	ktsimage_istockphoto.com, "Logo WHO", http://www.who.int/ , "Logo FAO", http://www.fao.org/ ,"Logo UNDOALOS"
Slide 29	Сергей_Хакимуллин_istockphoto.com